J. EGYPT., SOC. PHARMACOL., EXP., THER., VOL. 11, NO. 1, JAN. 1992. PROMOTION OF PEPTIC ULCER HEALING BY METRONIDAZOLE EKRAM EL-ASSIOUTY, NABIL A. KHATTAB, EL-METWALLY EL-SHAHAWY YEHIA SADDIK, ATEF IBRAHIM AND AHMED SALEH. DEPARTMENT OF INTERNAL MEDICINE, BENHA FACULTY OF MEDICINE A BSTRA CT THIS STUDY WAS CARRIED OUT ON 60 PATIENTS HAVING ENDOSCOPICALLY PROVEN CHRONIC ACTIVE DUODE¬NAL ULCER. THEY WERE DIVIDED INTO THREE GROUPS: GROUP I, RECEIVED METRONIDAZOLE IN A DOSE OF 500MG BID FOR 10 DAYS ON TWO SUCCESSIVE MONTHS AND CIMETIDINE IN A DOSE OF 800 MG DAILY FOR TWO MONTHS, GROUP II, TREATED WITH CIMETIDINE AND GROUP HI, RECEIVED ANTIACIDS AND METRONIDAZOLE. TWO MONTHS AFTER DRUG THERAPY ENDOSCOPIC AND HISTO-PATHOLOGIC STUDY SHOWED COMPLETE HEALING OF PEPTIC ULCER IN 90% IN GROUP I, 60% IN GROUP II AND 40% IN GROUP III. THEREFORE, METRONIDAZOLE HAS A ROLE IN PEPTIC ULCER TREATMENT, ITS ADDITION TO CIMETI¬DINE AUGMENTS PEPTIC ULCER HEALING. HENCE IT CAN BE USED AS AN ADJUVANT THERAPY TO PROMOTE PEPTIC ULCER HEALING.